Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 4/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6324606 | 0.89 | AOC3 (0.46) | AOC3MEN1KMT2AKDM4ERECQL | |
| SCHEMBL6317820 | 0.81 | AOC3 (0.49) | AOC3MEN1KMT2ARECQLAPP | |
| SCHEMBL6479388 | 0.77 | AOC3 (0.74) | AOC3 | |
| SCHEMBL3611926 | 0.77 | KDM4E (0.61) | KDM4ERECQLAPP | |
| SCHEMBL12703538 | 0.77 | KDM4E (0.61) | KDM4ERECQLAPP | |
| SCHEMBL11499413 | 0.76 | TAAR1 (0.48) | AOC3MEN1KMT2AKDM4ERECQL | |
| SCHEMBL13981330 | 0.76 | KDM4E (0.50) | MEN1KMT2AKDM4ERECQLAPP | |
| SCHEMBL18127062 | 0.76 | KDM4E (0.50) | MEN1KMT2AKDM4ERECQLAPP | |
| SCHEMBL15275317 | 0.76 | KDM4E (0.50) | MEN1KMT2AKDM4ERECQLAPP | |
| SCHEMBL18682251 | 0.76 | MAPT (0.44) | KDM4ERECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852731-B2 | Antiviral compounds | PFIZER (US) | 2005-02-08 | — | — | US | claimed |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY | 2004-12-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, IRF3, IFNAR1 | AOC3 4410/4885MEN1 1462/4885KMT2A 2402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.